BCR and neoplasm: In these U-CLL, pre-treatment of tumor cells with γ-secretase inhibitor (DAPT) decreases sIgM levels and signaling capacity, suggesting that the increased BCR signaling capacity is also supported by NOTCH1 stabilization [100].